Quarterly report pursuant to Section 13 or 15(d)

SETTLEMENT LIABILITY (Details Narrative)

v3.22.2
SETTLEMENT LIABILITY (Details Narrative) - USD ($)
$ in Thousands
Nov. 12, 2021
Jun. 30, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]      
Restricted Cash   $ 5,891 $ 5,891
REGENXBIO [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Settlement Liabilities, Current $ 30,000    
Loss Contingency, Settlement Agreement, Terms (1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.    
Debt Instrument, Interest Rate, Stated Percentage   9.60%  
Long-Term Debt, Current Maturities   $ 4,800  
Long-Term Debt, Excluding Current Maturities   4,000  
Restricted Cash   $ 5,000